AstronauTx Appoints Dr. Michelle Mellion as CMO to Lead Novel Sleep-Based Alzheimer's Therapeutics into Clinical Development
核心洞察
AstronauTx (搜索) has appointed Dr. Michelle Mellion as Chief Medical Officer, bringing over 20 years of neurology and clinical development experience to advance the company's sleep architecture (搜索)-targeting therapeutics.
The company is developing first-in-class therapies that target sleep architecture (搜索) as a potential disease-modifying strategy for Alzheimer's disease (搜索) and other neurological disorders (搜索).
AstronauTx (搜索)'s innovative approach uses EEG-based sleep architecture (搜索) metrics and advanced data analytics to improve slow-wave sleep (搜索) quality and potentially slow cognitive decline.
AstronauTx (搜索) Ltd, a biotechnology company developing therapeutics to treat Alzheimer's disease (搜索) and other neurological disorders (搜索) by improving sleep architecture (搜索), has announced the appointment of Dr. Michelle Mellion as Chief Medical Officer and Deb Gouveia as Vice President, Clinical Operations and Development Strategy. The appointments mark a significant milestone as the company prepares to advance its lead programmes into clinical development.
Experienced Leadership for Novel Therapeutic Approach
Dr. Mellion brings more than two decades of experience across academia and the biotechnology industry as a seasoned neurologist and clinical development leader. She has demonstrated a strong track record of advancing innovative therapies for neurological and rare diseases, including neuromuscular disorders (搜索).
Most recently, Dr. Mellion held Chief Medical Officer roles at PepGen and EveryONE Medicines (搜索), where she led clinical development efforts for oligonucleotide therapeutics and individualised medicines for ultra-rare conditions. Earlier in her career, she held positions at Biogen, Vertex Pharmaceuticals and Fulcrum Therapeutics, contributing to programmes spanning remyelination, pain and facioscapulohumeral muscular dystrophy (搜索) (FSHD).
Ms. Gouveia brings more than 25 years of experience building and leading clinical operations, regulatory, quality, and development infrastructure across emerging biotechnology companies.
Targeting Sleep Architecture as Disease-Modifying Strategy
AstronauTx (搜索)'s approach represents a novel therapeutic category at the intersection of sleep biology and neurodegenerative disease (搜索). The company's thesis is that changes in sleep architecture (搜索) underpin disease and that sleep is a modifiable risk factor for chronic neurodegeneration. By improving slow wave sleep quality, the company aims to slow cognitive decline associated with aging and dementia (搜索).
"AstronauTx (搜索) represents a rare opportunity to help define an entirely new therapeutic category at the intersection of sleep biology and neurodegenerative disease (搜索)," said Dr. Mellion. "The Company's innovative approach to leveraging slow-wave sleep (搜索) modulation as a potential disease-modifying strategy is both scientifically compelling and strategically differentiated, and I am excited to work with the team to advance these programmes into clinical development."
Quantifiable Biological Endpoints Drive Development
The company's approach is grounded in the use of quantifiable biological endpoints, including EEG-based sleep architecture (搜索) metrics, combined with advanced data analytics to better understand the relationship between sleep and neurodegenerative disease (搜索). This methodology includes measurable improvements in cognitive function and glymphatic flow (搜索) as key indicators of therapeutic efficacy.
AstronauTx (搜索) is preparing to initiate clinical development of its pipeline of first-in-class therapies targeting sleep architecture (搜索) as a treatment for Alzheimer's disease (搜索) and related neurological conditions.
Strong Financial Foundation and Leadership Vision
Founded by SV Health's Dementia (搜索) Discovery Fund, AstronauTx (搜索) completed a £48 million/$61 million Series A financing in October 2023, led by the Novartis Venture Fund (搜索), with participation from SV's Dementia Discovery Fund, MPM BioImpact, Brandon Capital, EQT Life Sciences and Bristol Myers Squibb (搜索).
"Michelle's appointment marks an important milestone for AstronauTx (搜索)," commented Jane Rhodes, Chief Executive Officer at AstronauTx. "Her track record in advancing therapies for neurological and rare diseases aligns strongly with our ambition to develop transformative treatments targeting sleep architecture (搜索). As we build out our clinical capabilities and progress our pipeline, the appointments of Michelle and Deb strengthen the expertise driving our transition into clinical‑stage development."
Dr. Mellion holds an honours degree in molecular biology from Colgate University and a medical degree from Wake Forest University School of Medicine, followed by advanced clinical training at Brown University. In her role as CMO at AstronauTx (搜索), she will lead the clinical strategy and development activities, working closely with the executive and leadership teams to advance the company's pipeline into the clinic.